カテゴリー： Inkwood Research, 世界, 医療/バイオ

世界の皮膚がん診断市場2023-2032

◆英語タイトル：GLOBAL SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032

Inkwood Researchが発行した調査報告書（INK23JUL014）◆商品コード：INK23JUL014
◆発行会社（リサーチ会社）：Inkwood Research
◆発行日：2023年6月16日
◆ページ数：229
◆レポート形式：英語 / PDF
◆納品方法：Eメール
◆調査対象地域：グローバル
◆産業分野：医療
◆販売価格オプション（消費税別）
Single UserUSD2,500 ⇒換算￥380,000見積依頼/購入/質問フォーム
Multi LicenseUSD3,000 ⇒換算￥456,000見積依頼/購入/質問フォーム
Enterprisewide PriceUSD4,500 ⇒換算￥684,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可）
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

Inkwood Research社の本調査資料では、皮膚がん診断の世界市場が2023年〜2032年の間に年平均成長率7.13%を記録すると予測しています。本資料は、皮膚がん診断の世界市場について調べ、調査範囲・調査手法、エグゼクティブサマリー、市場動向、主要分析、種類別（メラノーマ、非メラノーマ）分析、性別（男性、女性）分析、スクリーニング別（皮膚生検、皮膚鏡検査、リンパ腺、生検画像検査、血液検査）分析、地域別（北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ、アメリカ、カナダ、イギリス、ドイツ、フランス、イタリア、スペイン、中国、日本、インド、韓国、インドネシア、その他地域）分析、競争状況などの項目を掲載しています。また、AMLO BIOSCIENCES LIMITED、BIOMERIEUX SA、CASTLE BIOSCIENCES INC、DERMLITE LLC、DERMTECH INC、F. HOFFMANN-LA ROCHE LTD、MICHELSON DIAGNOSTICS LTDなどの企業情報が含まれています。
・調査範囲・調査手法
・エグゼクティブサマリー
・市場動向
・主要分析
・世界の皮膚がん診断市場規模：種類別
- メラノーマの市場規模
- 非メラノーマの市場規模
・世界の皮膚がん診断市場規模：性別
- 男性における市場規模
- 女性における市場規模
・世界の皮膚がん診断市場規模：スクリーニング別
- 皮膚生検の市場規模
- 皮膚鏡検査の市場規模
- リンパ腺の市場規模
- 生検画像検査の市場規模
- 血液検査の市場規模
・世界の皮膚がん診断市場規模：地域別
- 北米の皮膚がん診断市場規模
- ヨーロッパの皮膚がん診断市場規模
- アジア太平洋の皮膚がん診断市場規模
- 中南米の皮膚がん診断市場規模
- 中東/アフリカの皮膚がん診断市場規模
- アメリカの皮膚がん診断市場規模
- カナダの皮膚がん診断市場規模
- イギリスの皮膚がん診断市場規模
- ドイツの皮膚がん診断市場規模
- フランスの皮膚がん診断市場規模
- イタリアの皮膚がん診断市場規模
- スペインの皮膚がん診断市場規模
- 中国の皮膚がん診断市場規模
- 日本の皮膚がん診断市場規模
- インドの皮膚がん診断市場規模
- 韓国の皮膚がん診断市場規模
- インドネシアの皮膚がん診断市場規模
- その他地域の皮膚がん診断市場規模
・競争状況

KEY FINDINGS
The global skin cancer diagnostics market is projected to grow with a CAGR of 7.13% during the forecast period 2023-2032. The market’s growth is mainly fueled by the increasing prevalence of skin cancer, the surging awareness about skin cancer diagnosis & treatment, as well as technological advancements in skin cancer diagnostic products.

MARKET INSIGHTS
Skin cancer diagnostics entails the segment of the healthcare industry that covers various technologies, products, and services associated with the diagnosis, assessment, and detection of skin cancer. Skin cancer diagnostics methods generally include an amalgamation of visual inspection, dermoscopy, clinical examination, and tissue samples’ histopathological analysis.
Advanced technologies, including artificial intelligence (AI), are being widely utilized for the development of innovative skin cancer detection systems, capable of identifying the condition more efficiently and accurately compared to conventional methods. For instance, DermTech developed an AI-powered skin cancer detection system termed Athena. The system has demonstrated high accuracy in terms of identifying skin cancer. As a result, such cutting-edge technological advancements in skin cancer diagnostic products are projected to play an essential role in fueling the global skin cancer diagnostics market growth during the forecast period.

REGIONAL INSIGHTS
The global skin cancer diagnostics market growth analysis covers the study of North America, Europe, Asia-Pacific, and Rest of World. The market in North America is set to capture the highest revenue share by 2023. The regional market’s growth is propelled by key factors, such as significant investments in the research & development of skin cancer diagnostics products by major players as well as the increasing prevalence of skin cancer.

COMPETITIVE INSIGHTS
The industrial rivalry in the global skin cancer diagnostics market is expected to be high during the forecast period. Moreover, players with a larger product portfolio and significant R&D investments create strong competition in the global market. Some of the top companies operating in the market include DermTech Inc, Michelson Diagnostics Ltd, NeraCare GmbH, etc.

Our report offerings include:
• Explore key findings of the overall market
• Strategic breakdown of market dynamics (Drivers, Restraints, Opportunities, Challenges)
• Market forecasts for a minimum of 9 years, along with 3 years of historical data for all segments, sub-segments, and regions
• Market Segmentation caters to a thorough assessment of key segments with their market estimations
• Geographical Analysis: Assessments of the mentioned regions and country-level segments with their market share
• Key analytics: Porter’s Five Forces Analysis, Vendor Landscape, Opportunity Matrix, Key Buying Criteria, etc.
• The competitive landscape is the theoretical explanation of the key companies based on factors, market share, etc.
• Company profiling: A detailed company overview, product/services offered, SCOT analysis, and recent strategic developments

❖ レポートの目次 ❖

TABLE OF CONTENTS
1. RESEARCH SCOPE & METHODOLOGY
1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS
2. EXECUTIVE SUMMARY
2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
2.5. MAJOR MARKET FINDINGS
2.5.1. INCREASING APPLICATION OF AI AND MACHINE LEARNING IN SKIN CANCER DIAGNOSIS TOOLS
2.5.2. EXPANDING DEMAND FOR SKIN CANCER DIAGNOSTICS IN AUSTRALIA
3. MARKET DYNAMICS
3.1. KEY DRIVERS
3.1.1. INCREASING PREVALENCE OF SKIN CANCER
3.1.2. GROWING AWARENESS ABOUT SKIN CANCER DIAGNOSIS & TREATMENT
3.1.3. TECHNOLOGICAL ADVANCEMENTS IN SKIN CANCER DIAGNOSTIC PRODUCTS
3.2. KEY RESTRAINTS
3.2.1. HIGH COSTS ASSOCIATED WITH SKIN CANCER TREATMENTS
3.2.2. STRINGENT REGULATORY FRAMEWORK
3.2.3. LACK OF SKILLED MEDICAL PROFESSIONALS
4. KEY ANALYTICS
4.1. PARENT MARKET ANALYSIS
4.2. KEY MARKET TRENDS
4.3. PORTER’S FIVE FORCES ANALYSIS
4.3.1. BUYERS POWER
4.3.2. SUPPLIERS POWER
4.3.3. SUBSTITUTION
4.3.4. NEW ENTRANTS
4.3.5. INDUSTRY RIVALRY
4.4. GROWTH PROSPECT MAPPING
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
4.6.1. RESEARCH AND DEVELOPMENT
4.6.2. MANUFACTURING
4.6.3. MARKETING AND SALES
4.6.4. DISTRIBUTION AND LOGISTICS
4.6.5. TRAINING AND SUPPORT
5. MARKET BY TYPE
5.1. MELANOMA
5.2. NON-MELANOMA
6. MARKET BY GENDER
6.1. MALE
6.2. FEMALE
7. MARKET BY SCREENING TYPE
7.1. SKIN BIOPSY
7.2. DERMATOSCOPY
7.3. LYMPH NODE
7.4. BIOPSY IMAGING TESTS
7.5. BLOOD TESTS
8. GEOGRAPHICAL ANALYSIS
8.1. NORTH AMERICA
8.1.1. MARKET SIZE & ESTIMATES
8.1.2. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET DRIVERS
8.1.3. NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
8.1.4. KEY PLAYERS IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
8.1.5. COUNTRY ANALYSIS
8.1.5.1. UNITED STATES
8.1.5.1.1. UNITED STATES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.1.5.2. CANADA
8.1.5.2.1. CANADA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2. EUROPE
8.2.1. MARKET SIZE & ESTIMATES
8.2.2. EUROPE SKIN CANCER DIAGNOSTICS MARKET DRIVERS
8.2.3. EUROPE SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
8.2.4. KEY PLAYERS IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
8.2.5. COUNTRY ANALYSIS
8.2.5.1. UNITED KINGDOM
8.2.5.1.1. UNITED KINGDOM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.2. GERMANY
8.2.5.2.1. GERMANY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.3. FRANCE
8.2.5.3.1. FRANCE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.4. ITALY
8.2.5.4.1. ITALY SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.5. SPAIN
8.2.5.5.1. SPAIN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.6. NORDIC COUNTRIES
8.2.5.6.1. NORDIC COUNTRIES SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.7. BELGIUM
8.2.5.7.1. BELGIUM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.8. POLAND
8.2.5.8.1. POLAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.2.5.9. REST OF EUROPE
8.2.5.9.1. REST OF EUROPE SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3. ASIA-PACIFIC
8.3.1. MARKET SIZE & ESTIMATES
8.3.2. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET DRIVERS
8.3.3. ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
8.3.4. KEY PLAYERS IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
8.3.5. COUNTRY ANALYSIS
8.3.5.1. CHINA
8.3.5.1.1. CHINA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.2. JAPAN
8.3.5.2.1. JAPAN SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.3. INDIA
8.3.5.3.1. INDIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.4. SOUTH KOREA
8.3.5.4.1. SOUTH KOREA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.5. INDONESIA
8.3.5.5.1. INDONESIA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.6. THAILAND
8.3.5.6.1. THAILAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.7. VIETNAM
8.3.5.7.1. VIETNAM SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.8. AUSTRALIA & NEW ZEALAND
8.3.5.8.1. AUSTRALIA & NEW ZEALAND SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.3.5.9. REST OF ASIA-PACIFIC
8.3.5.9.1. REST OF ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.4. REST OF WORLD
8.4.1. MARKET SIZE & ESTIMATES
8.4.2. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET DRIVERS
8.4.3. REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET CHALLENGES
8.4.4. KEY PLAYERS IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
8.4.5. REGIONAL ANALYSIS
8.4.5.1. LATIN AMERICA
8.4.5.1.1. LATIN AMERICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
8.4.5.2. MIDDLE EAST & AFRICA
8.4.5.2.1. MIDDLE EAST & AFRICA SKIN CANCER DIAGNOSTICS MARKET SIZE & OPPORTUNITIES
9. COMPETITIVE LANDSCAPE
9.1. KEY STRATEGIC DEVELOPMENTS
9.1.1. PRODUCT LAUNCHES & DEVELOPMENTS
9.1.2. PARTNERSHIPS & AGREEMENTS
9.2. COMPANY PROFILES
9.2.1. AMLO BIOSCIENCES LIMITED
9.2.2. BIOMERIEUX SA
9.2.3. CASTLE BIOSCIENCES INC
9.2.4. DERMLITE LLC
9.2.5. DERMTECH INC
9.2.6. F. HOFFMANN-LA ROCHE LTD
9.2.7. MICHELSON DIAGNOSTICS LTD
9.2.8. NERACARE GMBH
9.2.9. SKYLINEDX BV
9.2.10. VERISKIN INC

LIST OF TABLES
TABLE 1: MARKET SNAPSHOT – SKIN CANCER DIAGNOSTICS
TABLE 2: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 3: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 4: GLOBAL MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 5: GLOBAL MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 6: GLOBAL NON-MELANOMA MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 7: GLOBAL NON-MELANOMA MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 8: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 9: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GENDER, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 10: GLOBAL MALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 11: GLOBAL MALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 12: GLOBAL FEMALE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 13: GLOBAL FEMALE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 14: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 15: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY SCREENING TYPE, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 16: GLOBAL SKIN BIOPSY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 17: GLOBAL SKIN BIOPSY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 18: GLOBAL DERMATOSCOPY MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 19: GLOBAL DERMATOSCOPY MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 20: GLOBAL LYMPH NODE MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 21: GLOBAL LYMPH NODE MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 22: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 23: GLOBAL BIOPSY IMAGING TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 24: GLOBAL BLOOD TESTS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 25: GLOBAL BLOOD TESTS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 26: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 27: GLOBAL SKIN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 28: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 29: NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 30: KEY PLAYERS OPERATING IN NORTH AMERICA SKIN CANCER DIAGNOSTICS MARKET
TABLE 31: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 32: EUROPE SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 33: KEY PLAYERS OPERATING IN EUROPE SKIN CANCER DIAGNOSTICS MARKET
TABLE 34: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 35: ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET, BY COUNTRY, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 36: KEY PLAYERS OPERATING IN ASIA-PACIFIC SKIN CANCER DIAGNOSTICS MARKET
TABLE 37: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, HISTORICAL YEARS, 2018-2022 (IN $ MILLION)
TABLE 38: REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET, BY REGION, FORECAST YEARS, 2023-2032 (IN $ MILLION)
TABLE 39: KEY PLAYERS OPERATING IN REST OF WORLD SKIN CANCER DIAGNOSTICS MARKET
TABLE 40: LIST OF PRODUCT LAUNCHES & DEVELOPMENTS
TABLE 41: LIST OF PARTNERSHIPS & AGREEMENTS


❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
★リサーチレポート[ 世界の皮膚がん診断市場2023-2032(GLOBAL SKIN CANCER DIAGNOSTICS MARKET FORECAST 2023-2032)]についてメールでお問い合わせはこちらでお願いします。
◆関連リサーチレポート◆
  • 肺がん診断の世界市場2023年～2030年：がん種類別、検査別、エンドユーザー別、地域別
  • 次世代がん診断の世界市場2022年～2029年：技術別、用途別、がん種類別、機能別、地域別
  • 世界の子宮がん治療＆診断市場2023-2030：がん種類別（子宮内膜腺がん、腺扁平上皮がん、乳頭漿液性がん、子宮肉腫）、製品別（治療薬、診断薬）、地域別
  • 卵巣がん診断の世界市場2023年～2030年：診断種類別、がん種類別、エンドユーザー別、地域別
  • 非侵襲的がん診断のグローバル市場（～2027）：肺がん、乳がん、固形腫瘍、その他

    • ◆H&Iグローバルリサーチのお客様（例）◆